Stocklytics Platform
Asset logo for symbol AXSM
Axsome Therapeutics
AXSM53
$92.45arrow_drop_down0.91%-$0.85
Asset logo for symbol AXSM
AXSM53

$92.45

arrow_drop_down0.91%

Performance History

Chart placeholder
Key Stats
Open$93.99
Prev. Close$93.17
EPS-6.58
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range93.53
94.57
52 Week Range55.02
104.88
Ratios
EPS-6.58

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc (AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company's pipeline includes multiple product candidates targeting various CNS indications, including major depressive disorder (MDD), Alzheimer's disease, and smoking cessation. With a strong emphasis on innovative research and development, Axsome Therapeutics aims to address unmet medical needs and improve the lives of patients suffering from these debilitating conditions.
One of the key highlights of Axsome Therapeutics is its lead product candidate, AXS-05, which is being developed for the treatment of MDD. AXS-05 combines two FDA-approved drugs, bupropion and dextromethorphan, to create a unique and potentially highly effective therapy. Clinical trials have shown promising results, with AXS-05 demonstrating significant improvement in depressive symptoms compared to placebo. This could potentially provide a new treatment option for the millions of adults suffering from MDD.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Herriot Tabuteau M.D.
Headquarters
New York
Employees
393
Exchange
NASDAQ
add Axsome Therapeutics  to watchlist

Keep an eye on Axsome Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Axsome Therapeutics 's (AXSM) price per share?

The current price per share for Axsome Therapeutics (AXSM) is $92.45. The stock has seen a price change of -$0.85 recently, indicating a -0.91% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Axsome Therapeutics (AXSM)?

For Axsome Therapeutics (AXSM), the 52-week high is $104.89, which is 13.45% from the current price. The 52-week low is $55.02, the current price is 68.03% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Axsome Therapeutics (AXSM) a growth stock?

Axsome Therapeutics (AXSM) has shown an average price growth of -6.8% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Axsome Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Axsome Therapeutics (AXSM) stock price performance year to date (YTD)?

As of the latest data, Axsome Therapeutics (AXSM) has a year-to-date price change of 19.97%. Over the past month, the stock has experienced a price change of -0.96%. Over the last three months, the change has been 2.4%. Over the past six months, the figure is 19.17%. Looking at a longer horizon, the five-year price change stands at 236.55%.
help

Is Axsome Therapeutics (AXSM) a profitable company?

Axsome Therapeutics (AXSM) has a net income of -$239.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 90.37% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -44.13% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $270.6M, although specific revenue growth data is currently not available. The gross profit is $244.54M. Operating income is noted at -$231.82M. Furthermore, the EBITDA is -$244.62M.
help

What is the market capitalization of Axsome Therapeutics (AXSM)?

Axsome Therapeutics (AXSM) has a market capitalization of $4.39B. The average daily trading volume is 93.11, indicating the stock's liquidity and investor engagement.

News

Take Your Investments to a Whole New Level